Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness

Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations.

“These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology (“ULTC”) for electrophysiology (“EP”),” said Todd Usen, Chief Executive Officer of Adagio Medical. “Marie-Claude is a proven commercial leader with a track record at Baylis of introducing a disruptive technology and energy source as a small entrant into the established EP market and growing these into widely adopted tools for EP, which culminated in the acquisition of Baylis by Boston Scientific. Antwan brings over two decades of leadership experience building scalable, compliant manufacturing infrastructures for energy-based and catheter-based devices in high-growth organizations. Their complementary skills will be instrumental as we prepare for the commercial launch of our ULTC ablation platform.”

Marie-Claude Jacques, Senior Vice President of Global Sales, brings over 15 years of commercial leadership experience across electrophysiology and interventional cardiology with deep expertise in global market development, sales force build-out, and physician adoption of novel technologies. She most recently served as Chief Commercial Officer at Catheter Precision, where she led global sales and marketing for the commercial launches of VIVO™, a non-invasive 3D mapping system, and LockeT™, a venous closure device. Previously, Ms. Jacques was Vice President of Sales and Marketing at Baylis Medical, where she built and led a 100-person organization and helped scale the company’s electrophysiology and transseptal access portfolio to double-digit growth and over $170 million in annual revenue. She spent two years as a Vice President of sales at Boston Scientific after the Baylis acquisition. Ms. Jacques holds an MBA from Warwick Business School (UK), graduate certificates in Business Law (USC Gould School of Law) and Business Communication (Harvard Extension School) and recently completed the MIT Sloan Executive Program in Artificial Intelligence in Healthcare.

“It is an honor to be a member of this incredible team at Adagio and to be a part of the future of ULTC,” said Ms. Jacques. “I am excited to help build a world-class global commercial organization that will partner with electrophysiologists to redefine outcomes in complex arrhythmia patients with this powerful new tool,” said Ms. Jacques.

Antwan Gipson, Senior Vice President of Manufacturing and Operations brings over 20 years of experience leading manufacturing, quality, supply chain, and logistics across high-growth medical technology companies. Most recently, he served as Vice President of Operations and Quality Sciences at Decobolus Consultancy Group. Prior to that, he held senior leadership roles at Candesant Biomedical, Nano Precision Medical, and Tautona Group. Mr. Gipson has a proven track record of scaling manufacturing from proof-of-concept through commercial launch, increasing production capacity by ten to 100-fold in compressed timelines to support commercial launches, reducing cost of goods by up to 75%, and building audit-ready quality systems that have supported successful regulatory clearances. He holds a Doctorate in Business from CIU Irvine, an MBA specializing in Operations Analytics and Technology from Angelo State University, and a Bachelor’s of Science in Engineering and Technology from Northern Michigan University.

“Adagio’s technology platform presents a rare opportunity to combine precision engineering with transformative patient impact,” said Antwan Gipson, Senior Vice President, Manufacturing and Operations. “I look forward to building a scalable, cost-efficient, and high-quality manufacturing infrastructure that not only supports efficient global supply, but enables attractive gross margins and long-term commercial sustainability.”

“The addition of Marie-Claude and Antwan underscores our focus on execution, scale, and disciplined commercialization,” added Usen. “Their combined leadership will be central to achieving our commercialization goals in 2026 and beyond and to creating lasting value for our patients, customers and shareholders.”

About Adagio Medical Holdings, Inc.

Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cardiac (ULTC) ablation technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.

About FULCRUM VT

FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.

Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning: Adagio’s strategy, future operations, , expected timing and results of clinical trials, prospects, plans and objectives of management; and the potential for FDA approval and commercialization of Adagio’s product candidates. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Adagio’s business are described in detail in Adagio’s Securities and Exchange Commission (“SEC”) filings, including in its Annual Report on Form 10-K for the full-year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Adagio makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Adagio disclaims any obligation to update these statements except as may be required by law.

Contacts

Debbie Kaster

Chief Financial Officer and Chief Business Officer

dkaster@adagiomedical.com